Close

Jump to:

  • Navigation
  • Content
  • Footer
Mimetis hero image

Mimetis

Follow

We design & manufacture naturally inspired biomaterials for bone regeneration in dental and orthopaedics.

145%
 - 
Funded 31 Dec 2018
€120,005 target
€190,443 from 288 investors
More
Less

Business overview

Location Barcelona, Spain
Social media
Website www.mimetis.com
Sectors Healthcare Non-Digital Mixed B2B/B2C
Company number ESB66143157
Incorporation date 23 Oct 2013
More
Less

Investment summary

Type Convertible
Discount 20%
Share price N/A
UK tax relief N/A
  • Idea
  • Market
  • Team
  • Updates
  • Investors 288
  • Discussion
  • Documents

Learn more about convertible campaigns.

Idea

Introduction

Mimetis designs, manufactures and commercialises bone regenerative solutions in the dental and orthopaedic fields.

The company was incorporated in 2013 as a spin-off of the Technical University of Catalonia, Barcelona, with Dr.Ginebra as the spearhead and acting President.

Mimetis uses biomimicry as its technological inspiration, synthetically manufacturing a bone graft that closely mimics the natural bone of the patient in order to regenerate it physiologically.

As of today, Mimetis is up and running with its own manufacturing line, increasing sales revenues and an experienced team onboard.

The company is now:

- Expanding its portfolio of bone regenerative solutions with a unique 3D Printing technology for patient-specific implants.
- Growing commercially towards orthopaedics and additional territories.

Convertible Details

This investment round is being raised by way of a convertible instrument. The key terms that apply to the Mimetis convertible are as follows:

• Discount – conversion at a 20% discount to the valuation set by a Trigger Event.

• This convertible has a valuation cap of €10m. Please note that the discount does not apply to the valuation cap. If the Trigger Event is at a valuation of more than €10m, then the convertible will convert at the lower of:
- the price set by the Trigger Event less the 20% discount; and
- a valuation of €10m.

• Conversion is triggered by the follow Trigger Events:

o An Equity Fundraise – defined as the Company raising investment capital of at least €800,000 from one transaction or a series of transactions, in exchange for the company issuing equity Shares. The Seedrs fundraise does not count as a transaction.

o A Change of Control of the company (transfer of more than 50% of the share capital); or

o An IPO – being a listing of the company’s shares on a recognised stock market or secondary market.

• The Longstop Date is 12 months from the date of the convertible agreement. If conversion has not been triggered by the Longstop Date shares will be issued on the Longstop Date at a valuation based on the lower of:
(i) the lowest price of any Equity Share issued after the date of this Agreement; and
(ii) a pre-money company valuation of €3,666,985 on a fully diluted basis (this is based on the valuation of Mimetis' last funding round).

The convertible would also convert to equity at this price in the event of winding up or liquidation of the company.

Intended impact

Global ageing is a clear trend and is linked to a growing need for bone regenerating solutions. In the dental field, bones need to be regenerated or replaced before placing a dental implant. In the orthopaedics field, bone grafting is used in spinal fusion procedures.

The existing solutions have limitations such as:
• Ethics: Animal- or human-derived bone grafting solutions raise major ethical, cultural or religious issues.
• Efficacy: The existing solutions are biomaterials for bone filling instead of temporal tools for physiological bone regeneration.
• Anatomy: Existing solutions do not allow implantation of biomimetic patient-specific bone regenerative solutions

Mimetis serves the unmet needs developing and marketing the latest generation of bone regenerative solutions. This pursues a triple aim (better care, better health, lower cost), and the medical providers’ specific objectives around quality, safety and cost.

Here is some educational content for patients on how bone grafts work:

Substantial accomplishments to date

To date, Mimetis reached the following milestones:

• Technological background
- A team with the benefit of 15 years of academic research into the workings and discovery of biomedical engineering.

- Regulatory approvals for Europe have been received (CE, ISO13485). To our knowledge this is the first biomimetic product in the market.

• Product & Commercial traction
- Our view is that the existing synthetic solutions may solve ethical concerns but lack clinical efficacy. Mimetis’ aim is to use innovative biomimetic technology to provide patients with ethical, synthetically sourced, clinically-efficient bone regenerative solution.

- A patient-specific, biomimetic 3D-printed bone regenerative solutions for complex cases: MimetikOss 3D.

- Global option agreement in the dental field

- National increasing sales year on year

- 200k in Sales (Product & Services).

• Financials/Corporate
- €800k of funding from founders and strategic investors

- €1M of grants from the European and Spanish institutions.

- €128k accumulated tax credit.

- Dr.Maria Pau Ginebra was a finalist of the Women Innovator Prize organized by the European Union 2018.

Monetisation strategy

Mimetis Biomaterials designs, manufactures and commercializes bone regenerative solutions. MimetikOss Granules' design is based on biomimicry to regenerate bone. The product is available in European markets. The company manufactures the granules using a proprietary trade secret in an ISO7 cleanroom at its manufacturing site based in the outskirts of Barcelona, Spain. Also, it owns a customised 3D-printing set of machines to print personalised bone grafts.

The company’s sources of revenue are:
> Direct sales in dental and orthopaedics (Spain)
> Sales through sales representatives (Dental, Spain)
> Sales through distribution agreements (Orthopaedics, Spain)
> Upcoming option agreement in place (Confidential)
> Services provided to dental implant companies

Use of proceeds

The funds gathered support the first step taken towards a larger investment 2019. It will help us to reach key objectives such as:

> The 1st human case using 3D-printed biomimetic technology
> Intermediate results of the ongoing randomized clinical trials
> Potential execution of a global option to exclusive distribution in the dental field
> Initial orthopaedic market entry
> Packaging update to match orthopedics needs

All the aforementioned items are high-value areas for the company. The 6th activity of the Company during this time span is the preparation of this Series A investment round.

Subsequently, the amount raised in the campaign would allow for continuing development of the company. Mimetis have two soft bank loans of €100k each. The loans will be fully reimbursed Q2 2019 but this fundraising round will not be used to pay back these loans.

Market

Target market

Our users are technical buyers, with deep understanding and knowledge of bone regenerative solutions:

• Dental surgeons: Bone grafting accompanies dental implants.
• Orthopaedic/Craniomaxillofacial surgeons: Spinal fusions and bone regenerating procedures are increasingly common and linked to global healthy ageing needs in developed countries. Furthermore, patient-specific 3D-printed scaffolds prevent bone harvesting from the patient. The orthopaedic/CMF market is 4 fold the dental market globally.

In both markets, the appeal of the product is its uniqueness in the market being the first biomimetic bone regenerative solution as far as we are aware. Its clinical efficiency and synthetic sourcing are valued by customers.

Characteristics of target market

Mimetis is intended to have a global presence, with a special focus on Europe where 2 million bone grafts are performed each year. The EU BGS market is predicted to rise from $721m in 2016 to $1055m by 2025 (European BGS market forecast 2017-2025, Global Inf Inc Research).

The promising results in the dental sector support our vision to introduce a disruptive technology into craniomaxillofacial (CMF) and orthopaedics through patient-specific solutions.
Key market data is provided:
• Dental Bone Graft: A market worth $664m globally by 2021.
• CMF: The global CMF implants market is expected to grow at a CAGR of 6.2% from 2014 to 2020, to reach an estimated value of M$1498.6 in 2020 (Persistence Market Research study ‘Global Market Study on Cranio Maxillofacial Implants’, 2014).
• Orthopaedics: The orthopaedics market, 80% of the total global bone grafting market, is more mature, grows at a CAGR of approx 4.1%.

Marketing strategy

Mimetis commercializes its products in Spain through both direct sales and 15 external sales representatives. Our goal is to reach commercial agreements with medical devices distributors in the orthopaedic field (cost-effectiveness of the sales process, access to public calls...).
Our go-to-market strategy for patient-specific and standard products is the following:
• Lead generation through social media, website, newsletters and conferences.
• Technical adoption: using exceptional clinical and objective validation of the products and support from Key Opinion Leaders.
• Commercial adoption: price/volume negotiations to make the most of the direct manufacturer-distributor relationship.
• Loyalty: Tight follow-up of the customers and maintenance of high-quality standards (Mimetis is ISO 13485 Certified by BSI).

Competition strategy

As of today, the market is dominated by allografts (human-derived, preferred option in the US) and xenografts (animal-derived, preferred option in the EU). Our company differentiates using a biomimetic technological basis. It seeks to support it with exceptional clinical evidence.

• The competitive landscape for bone grafts substitutes (granules) includes:

- Ceramics (Zimmer Biomet, Teknimed)
- Coral (Corebone, Zimmer-Biomet, Biocora, Interpore)
- Composites (Insubri,Stryker)
- Demineralized bone matrix (DBM, Zimmer-Biomet, Allosource, XTANT Medical, SeaSpine),
- Xenografts (Straumann, Geistlich Pharma, Zimmer-Biomet)
- Allografts (DePuy Synthes, Strauman, Zimmer-Biomet)

• The competitive landscape for patient-specific products includes direct competitors (Xilloc, Innotere, Tissue Regeneration Systems) and substitutes solving the same problem (Depuy Synthes, KLS Martin).

Open an account to get access to the team members of Mimetis

Sign up

Already have an account? Log in

To comply with financial regulations, we can only show full campaign details to registered users.

Only shareholders can access this page

If you successfully purchase a share lot of this business, you will be granted access.

Buy shares

Only shareholders can access this page

If you successfully purchase a share lot of this business, you will be granted access.

Buy shares

Only shareholders can access this page

If you successfully purchase a share lot of this business, you will be granted access.

Buy shares

Only shareholders can access this page

If you successfully purchase a share lot of this business, you will be granted access.

Buy shares

Share on:

Investing involves risks, including loss of capital, illiquidity, lack of dividends and dilution, and should be done only as part of a diversified portfolio. Please read the Risk Warnings before investing. Investments should only be made by investors who understand these risks. Tax treatment depends on individual circumstances and is subject to change in future.

This campaign for Mimetis has been approved by Seedrs Limited (trading as Republic Europe) ("Republic Europe", "us" or "we"), as of 2 October 2018 as a financial promotion. Republic Europe is authorised and regulated by the Financial Conduct Authority with firm reference number 550317. In approving this campaign, Republic Europe has concluded that the information, taken as a whole, is "fair, clear and not misleading." This means that for factual statements we have reviewed evidence of their accuracy, and that for aspirational statements we believe they are phrased appropriately in light of their speculative nature. You should note that in the case of factual statements, the evidence we review is provided by the business, and we do not audit it, which means that we may not be able to identify forged or altered evidence. You should further note that in the case of aspirational statements, the nature of the type of businesses presented on the Republic Europe platform is such that they are likely to have high ambitions, and we may approve statements that convey those ambitions even where we do not believe, or we do not have a view on whether it is likely, that they will be fully realised. The pre-money valuation and investment sought in the campaign are those set by the business: they are not reviewed or established by us, and the valuation is not an independent view of what the business is worth. Given the nature and type of businesses presented on the Republic Europe platform, it is possible that the business has very little cash remaining prior to receiving this investment, and the investment sought may be necessary for the business's on-going existence.

Republic Europe does not make investment recommendations to you. No communications from Republic Europe, through this website or any other medium, should be construed as an investment recommendation. Further, nothing on this website shall be considered an offer to sell, or a solicitation of an offer to buy, any security to any person in any jurisdiction to whom or in which such offer, solicitation or sale is unlawful. Republic Europe does not provide legal, financial or tax advice of any kind. If you have any questions with respect to legal, financial or tax matters relevant to your interactions with Republic Europe, you should consult a professional adviser.

Tax Relief (SEIS)

This business is eligible for SEIS relief - providing qualifying investors with income tax relief of 50% of their investment and certain other tax reliefs. Tax treatment depends on individual circumstances and is subject to change in future. Click to learn more.

Tax Relief (EIS)

This business is eligible for EIS relief - providing qualifying investors with income tax relief of 30% of their investment and certain other tax reliefs. Tax treatment depends on individual circumstances and is subject to change in future. Click to learn more.

Valuation (pre-money)

Valuation rounded from Convertible

This is the fully-diluted pre-money valuation of the business (i.e. before the new investment comes in and including issued options and other equity interests). In contrast, the post-money valuation is based on inclusion of the new investment in the value.

It is calculated as the pre-money valuation plus the amount of new investment. e.g. If Company A is ascribed a pre-money valuation of £1,200,000 by prospective investors investing £300,000, its post-money valuation is £1,500,000.

The investee business is responsible for setting its own valuation, it has not been prescribed by Republic Europe.

Pitch type

Investing in a convertible campaign allows you to invest today, with your investment converting into equity in the future, at a discount compared to other investors.

Learn more about pitch type on Republic Europe

Equity Offered

The equity offered is the percentage of the company’s shares being issued in return for the amount of investment raised.

When the amount raised is less than 100%, the equity offered is based on the target raise. Once the company has raised over 100% it is based on the total raised.

In some scenarios, entrepreneurs may accept additional direct investment after closing their Republic Europe campaign. Provided this is within 6 months of the closing and on the same terms, we do not typically offer pre-emption rights on that extra investment (where you have the opportunity to invest again to maintain your percentage shareholding).

Learn more about investing and pre-emption rights.

Warning

You are following a link outside of europe.republic.com.

None of the information in constitutes part of the campaign and it has not been approved or reviewed by Republic Europe.

ContinueCancel